Cognitive impairment following chemotherapy for breast cancer: The impact of practice effect on results

Cerulla, Noemí; Arcusa, Àngels; Navarro, J. Blas; Osa, Núria de la; Garolera, Maite; Enero, Cristina; Chico, Gloria; Fernández-Morales, L.A.

doi:10.1080/13803395.2018.1546381

Cited by 29 publications

(19 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Future studies should explore the possibility that the changes in sucrose preference reflect anhedonia specifically and not paclitaxel-induced changes to the interoceptive state of the mice, which are partially refuted by the examination of tongue papillae and taste receptor gene expression in this study. These findings confirm clinical studies that report differential effects of chemotherapy on numerous cognitive processes and across time ( 37 , 38 ). Future evaluation of specific brain regions, as well as affective and cognitive processes, are required to better understand the impact of chemotherapy on cognition.…”

Section: Discussionsupporting

confidence: 87%

The Anti-Inflammatory Drug Aspirin Does Not Protect Against Chemotherapy-Induced Memory Impairment by Paclitaxel in Mice

et al. 2020

View full text Add to dashboard Cite

Inflammation has been proposed to play a causal role in chemobrain which—if true—would represent an opportunity to repurpose existing anti-inflammatory drugs for the prevention and treatment of chemobrain. Here, we show that the chemoagent paclitaxel induces memory impairment and anhedonia in mice within 24 h of treatment cessation, but inflammation is not present until 2 weeks after treatment. We find no evidence of brain inflammation as measured by cytokine analysis at any time point. Furthermore, treating with aspirin to block inflammation did not affect paclitaxel-induced memory impairment. These findings suggest that inflammation may not be responsible for memory impairment induced by paclitaxel. These results contrast with recent findings of a causal role for inflammation in cancer-induced memory deficits in mice that were prevented by treatment with oral aspirin, suggesting that cognitive impairment in cancer patients undergoing treatment may arise from multiple convergent mechanisms.

show abstract

Section: Discussionsupporting

confidence: 87%

The Anti-Inflammatory Drug Aspirin Does Not Protect Against Chemotherapy-Induced Memory Impairment by Paclitaxel in Mice

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Our study focused on brain intrinsic activity data obtained from rs-fMRI while prior studies focused on cognitive testing data [39] or brain structural data such gray matter changes in chemotherapy-treated patients [32]. Third, the lack of correlation in our CT group might be partially due to a chemotherapy-associated decrease in the practice effect from repeated administration of cognitive tests, whereas the HC participants may derive more benefit from practice [40].…”

Section: Discussionmentioning

confidence: 99%

Intrinsic brain activity changes associated with adjuvant chemotherapy in older women with breast cancer: a pilot longitudinal study

Chen

Jin

Patel

et al. 2019

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Most studies reported multiple cognitive domains and timepoints for each cognitive function. Eight of the 11 studies assessed cognitive function 6 months after completion of chemotherapy; of the remaining three, assessments were made 9 months (54), 1 year after completion of chemotherapy (46), and 13 months after initiation of chemotherapy (43). We did not conduct a separate analysis for the studies that reported on assessment of cognitive function at more than one time-point.…”

Section: Meta-analysismentioning

confidence: 99%

Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Purpose: This meta-analysis provides a longitudinal assessment of depression and cognitive impairment induced by taxane-based chemotherapy in women with breast cancer after 6 months of treatment. We highlighted the incidence and prevalence, the cognitive pattern in neuropsychological studies, and the relationship between chemotherapy-induced cognitive impairment and different risk factors. We estimated the effect sizes on each cognitive domain and differentiated effect sizes by each method of comparison of effects (i.e., baseline data, or control groups).Methods: The databases MEDLINE and Embase were searched for publications about taxane-related cognitive changes in patients with breast cancer published from 1980 to 2019. Cross-sectional and self-reported outcomes studies were excluded except for the depression item. Included studies were assessed for risk of bias with the Newcastle–Ottawa Scale. We estimated effect sizes for each cognitive domain and differentiated effect sizes by each method of comparison of effects. The review is reported in compliance with the PRISMA Statement; it was registered prospectively in PROSPERO as CRD42020163255.Results: Eleven studies meeting the criteria were analyzed, which resulted in a sample of 1,057 patients with breast cancer who received chemotherapy including 820 patients (77%) who received taxane-based chemotherapy. Attention and concentration, depression, and executive function domains had significant chemotherapy-induced impairment across all comparison types. Statistically significant improvement was found in language and verbal memory when comparing chemotherapy patients' test scores with baseline or matched controls. Taxane-based chemotherapy had a non-significant effect on processing speed, visual memory, visuospatial, and motor function domains.Conclusions: The occurrence of chemotherapy-induced cognitive impairment 6 months or more after the course of treatment in people with breast cancer is frequent in the domains of attention, executive function, and depression. Other domains appear stable or improve with time after treatment cessation.

show abstract

Cognitive impairment following chemotherapy for breast cancer: The impact of practice effect on results

Cited by 29 publications

References 47 publications

The Anti-Inflammatory Drug Aspirin Does Not Protect Against Chemotherapy-Induced Memory Impairment by Paclitaxel in Mice

The Anti-Inflammatory Drug Aspirin Does Not Protect Against Chemotherapy-Induced Memory Impairment by Paclitaxel in Mice

Intrinsic brain activity changes associated with adjuvant chemotherapy in older women with breast cancer: a pilot longitudinal study

Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis

Contact Info

Product

Resources

About